In-Hospital Mortality-Associated Factors of Thrombotic Antiphospholipid Syndrome Patients Requiring Intensive Care Unit Admission

Archive ouverte

Pineton de Chambrun, Marc | Larcher, R. | Pène, Frédéric | Argaud, Laurent | Mayaux, Julien | Jamme, Matthieu | Coudroy, Rémi | Mathian, Alexis | Gibelin, Aude | Azoulay, Elie | Tandjaoui-Lambiotte, Yacine | Dargent, Auguste | Beloncle, François-Michel | Raphalen, Jean-Herlé | Couteau-Chardon, Amélie | de Prost, Nicolas | Devaquet, Jérôme | Contou, Damien | Gaugain, Samuel | Trouiller, Pierre | Grange, Steven | Ledochowski, Stanislas | Lemarié, Jérémie | Faguer, Stanislas | Degos, Vincent | Luyt, Charles-Edouard | Combes, Alain | Amoura, Zahir

Edité par CCSD ; American College of Chest Physicians -

International audience. Background: The antiphospholipid syndrome (APS) is a systemic autoimmune disease defined by thrombotic events that can require ICU admission because of organ dysfunction related to macrovascular and/or microvascular thrombosis. Critically ill patients with thrombosis and APS were studied to gain insight into their prognoses and in-hospital mortality-associated factors.Methods: This French national, multicenter, retrospective study included all patients with APS and any new thrombotic manifestations admitted to 24 ICUs (January 2000-September 2018).Results: During the study period, 134 patients (male/female ratio, 0.4) with 152 APS episodes were admitted to the ICU (mean age at admission, 46.0 ± 15.1 years). In-hospital mortality of their 134 last episodes was 35 of 134 (26.1%). The Cox multivariable model retained certain factors (hazard ratio [95% CI]: age ≥ 40 years, 11.4 [3.1-41.5], P < .0001; mechanical ventilation, 11.0 [3.3-37], P < .0001; renal replacement therapy, 2.9 [1.3-6.3], P = .007; and in-ICU anticoagulation, 0.1 [0.03-0.3], P < .0001) as independently associated with in-hospital mortality. For the subgroup of definite/probable catastrophic APS, the Cox bivariable model (including the Simplified Acute Physiology Score II score) retained double therapy (corticosteroids + anticoagulant, 0.2 [0.07-0.6]; P = .005) but not triple therapy (corticosteroids + anticoagulant + IV immunoglobulins or plasmapheresis: hazard ratio, 0.3 [0.1-1.1]; P = .07) as independently associated with in-hospital mortality.Conclusions: In-ICU anticoagulation was the only APS-specific treatment independently associated with survival for all patients. Double therapy was independently associated with better survival of patients with definite/probable catastrophic APS. In these patients, further studies are needed to determine the role of triple therapy.

Suggestions

Du même auteur

Hematological features and alternate diagnoses in critically ill thrombotic antiphospholipid syndrome patients

Archive ouverte | Azoulay, Levi-Dan | CCSD

International audience. Objectives: Severe thrombotic antiphospholipid syndrome (APS) frequently affects the kidney, heart, and central nervous system. The precise frequency, clinical picture, differential diagnoses...

Prevalence, characteristics and outcome of cardiac manifestations in critically-ill antiphospholipid syndrome patients

Archive ouverte | Azoulay, Lévi-Dan | CCSD

International audience

Who? When? Where? How? Still the alpha and omega of extracorporeal cardiopulmonary resuscitation

Archive ouverte | Pineton de Chambrun, Marc | CCSD

International audience

Chargement des enrichissements...